Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TAK-079 in healthy volunteers
NCT02219256Phase 1Completed
- Sponsor
- Takeda
- Start
- Aug 2014
- Primary completion
- Apr 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mezagitamab in autoimmune disease (3 arms), sponsored by Takeda. Primary endpoints: Number of Participants Who Experience at Least 1 Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE), Number of Participants Who Meet the Takeda Development Centre (TDC) Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose and 2 more. Started Aug 2014; status: completed.
02
Drugs
mezagitamab
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT02219256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02219256.